SCHEMBL29832279

SCHEMBL29832279

CCOC(=O)c1sc(Nc2nc(-c3ccc(NC(=O)OC(C)(C)C)cc3)cc(N3CCC(O)CC3)n2)nc1C

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 6/20 0.69
▸ DHODH Q02127 5/20 0.44
▸ MAPT P10636 6/20 0.43
▸ KDM4E B2RXH2 5/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ LMNA P02545 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ NPC1 O15118 3/20 0.41
▸ HPGD P15428 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL291083 1.00 PDE5A (0.69) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL27950940 0.91 PDE5A (0.54) PDE5A
SCHEMBL291287 0.89 PDE5A (0.70) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL29831789 0.87 PDE5A (0.79) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL291110 0.87 PDE5A (0.79) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL292060 0.86 PDE5A (0.77) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL291286 0.86 PDE5A (0.77) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL290337 0.86 PDE5A (0.67) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL29831861 0.86 PDE5A (0.67) PDE5ADHODHMAPTKDM4EALDH1A1
SCHEMBL290089 0.86 PDE5A (0.76) PDE5ADHODHMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 — — EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 — — WO disclosed
CN-115192711-A Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2022-10-18 — — CN disclosed
CN-114984229-A Treatment of addiction and impulse control disorders using PDE7 inhibitors 奥默罗斯公司 2022-09-02 — — CN disclosed
Send feedback